FREIBURG, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov 27, 2018–German Accelerator Life Sciences Alumni company, SpinDiag, just announced the successful closing of 3 million Series A funding round. The Freiburg-based health tech startup addresses the challenge of patients introducing drug-resistant bacteria into hospitals. SpinDiag provides a rapid point-of-care screening system, SpinDiag one, to test high-risk patients for all relevant drug-resistances. The German Accelerator Life Sciences (GALS) program with its experienced mentor team and extensive network of partners and industry experts, contributed to the development of SpinDiag’s U.S. regulatory and market access strategy.
Quelle: German Accelerator Life Sciences (GALS) Alumni Company SpinDiag Closes € 3M Funding Round